Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 408.02 Billion KRW | 9.45% |
| 2022 | 372.79 Billion KRW | 8.39% |
| 2021 | 343.94 Billion KRW | 8.47% |
| 2020 | 317.07 Billion KRW | 9.28% |
| 2019 | 290.15 Billion KRW | 11.1% |
| 2018 | 261.15 Billion KRW | 13.48% |
| 2017 | 230.14 Billion KRW | 12.2% |
| 2016 | 205.11 Billion KRW | 11.32% |
| 2015 | 184.26 Billion KRW | 6.82% |
| 2014 | 172.49 Billion KRW | 11.01% |
| 2013 | 155.37 Billion KRW | 27.28% |
| 2012 | 122.07 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 491.41 Billion KRW | 18.84% |
| 2024 Q1 | 413.51 Billion KRW | 1.35% |
| 2023 Q2 | 403.54 Billion KRW | 2.47% |
| 2023 Q1 | 393.81 Billion KRW | 5.5% |
| 2023 FY | 408.02 Billion KRW | 9.45% |
| 2023 Q4 | 408.02 Billion KRW | 0.05% |
| 2023 Q3 | 407.82 Billion KRW | 1.06% |
| 2022 Q4 | 373.27 Billion KRW | -0.66% |
| 2022 FY | 372.79 Billion KRW | 8.39% |
| 2022 Q3 | 375.76 Billion KRW | 2.86% |
| 2022 Q2 | 365.3 Billion KRW | 1.06% |
| 2022 Q1 | 361.47 Billion KRW | 5.09% |
| 2021 Q3 | 343.63 Billion KRW | -0.55% |
| 2021 Q4 | 343.94 Billion KRW | 0.09% |
| 2021 FY | 343.94 Billion KRW | 8.47% |
| 2021 Q2 | 345.54 Billion KRW | 0.06% |
| 2021 Q1 | 345.33 Billion KRW | 8.91% |
| 2020 Q1 | 291.08 Billion KRW | 0.32% |
| 2020 Q3 | 308.29 Billion KRW | 6.26% |
| 2020 Q4 | 317.07 Billion KRW | 2.85% |
| 2020 Q2 | 290.12 Billion KRW | -0.33% |
| 2020 FY | 317.07 Billion KRW | 9.28% |
| 2019 Q3 | 283.17 Billion KRW | 4.39% |
| 2019 Q2 | 271.27 Billion KRW | 2.22% |
| 2019 Q1 | 265.39 Billion KRW | 1.62% |
| 2019 FY | 290.15 Billion KRW | 11.1% |
| 2019 Q4 | 290.15 Billion KRW | 2.46% |
| 2018 Q2 | 244.59 Billion KRW | 1.34% |
| 2018 Q1 | 241.36 Billion KRW | 4.87% |
| 2018 Q4 | 261.15 Billion KRW | 7.84% |
| 2018 FY | 261.15 Billion KRW | 13.48% |
| 2018 Q3 | 242.16 Billion KRW | -0.99% |
| 2017 FY | 230.14 Billion KRW | 12.2% |
| 2017 Q2 | 215.54 Billion KRW | 2.18% |
| 2017 Q3 | 222.89 Billion KRW | 3.41% |
| 2017 Q4 | 230.14 Billion KRW | 3.25% |
| 2017 Q1 | 210.94 Billion KRW | 2.84% |
| 2016 Q3 | 199.29 Billion KRW | 2.94% |
| 2016 FY | 205.11 Billion KRW | 11.32% |
| 2016 Q1 | 187.8 Billion KRW | 1.92% |
| 2016 Q4 | 205.11 Billion KRW | 2.92% |
| 2016 Q2 | 193.61 Billion KRW | 3.09% |
| 2015 Q1 | 171.17 Billion KRW | -0.76% |
| 2015 Q4 | 184.26 Billion KRW | 2.17% |
| 2015 Q3 | 180.35 Billion KRW | 4.24% |
| 2015 Q2 | 173.01 Billion KRW | 1.08% |
| 2015 FY | 184.26 Billion KRW | 6.82% |
| 2014 Q1 | 159.83 Billion KRW | 2.87% |
| 2014 FY | 172.49 Billion KRW | 11.01% |
| 2014 Q3 | 168.44 Billion KRW | 3.65% |
| 2014 Q2 | 162.51 Billion KRW | 1.68% |
| 2014 Q4 | 172.49 Billion KRW | 2.4% |
| 2013 Q1 | 118.2 Billion KRW | -3.17% |
| 2013 Q2 | 123.44 Billion KRW | 4.43% |
| 2013 FY | 155.37 Billion KRW | 27.28% |
| 2013 Q3 | 127.82 Billion KRW | 3.55% |
| 2013 Q4 | 155.37 Billion KRW | 21.55% |
| 2012 FY | 122.07 Billion KRW | 0.0% |
| 2012 Q4 | 122.07 Billion KRW | 19.05% |
| 2012 Q3 | 102.54 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 52.79 Billion KRW | -672.889% |
| ST Pharm Co.,Ltd. | 686.83 Billion KRW | 40.594% |
| ABL Bio Inc. | 160.14 Billion KRW | -154.784% |
| Cellid, Co., Ltd. | 63.92 Billion KRW | -538.31% |